london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Efficacy of dexamethasone implant (Ozurdex©) after failed anti-VEGF therapy in a patient with chronic diabetic macular edema

Poster Details

First Author: A.K.Cordes GERMANY

Co Author(s):    H. Furjani   H.R. Koch               0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

Treating Diabetic macular edema requires continuous monitoring and repeated injections of intravitreal medication. Anti-VEGF drugs require close monitoring and often repeated re-injections. Especially international patients cannot adhere to short sequence treatment and control intervals. A safe and long-lasting therapy is essential in achieving good anatomical and functional results.

Setting:

This study analyses the results of 5 eyes which were treated at the hochkreuz-eye-clinic Bonn from 2011 till today.

Methods:

We analyzed 5 eyes of 3 patients with long lasting diabetic maculopathy. The initial treatment was initiated with Bevacizumab. This treatment was changed to Ozurdex©-therapy in the course of the treatment.

Results:

During the initial Bevacizumab therapy the visual acuity (VA) increased on average -2.43 (+/- 6,4) ETDRS letters. The central retinal thickness (CRT) increased 51.6µm (+/- 106.8). After the switch to the dexamethasone implant the VA increased on average 9.6 (+/- 5.8) EDTRS letters and the CRT decreased -232.4µm (+/- 120.9). The re-injection interval in the Bevacizumab group was greater than 54 days while the Ozurdex©-therapy has to be repeated every 121 days to achieve the result.

Conclusions:

The long-lasting dexamethasone implant is a potent drug in treatment of diabetic macular edema. It can lead to anatomical and functional improvement in chronic macular edema even after failure of anti-VEGF therapy. It is a valuable option especially in patients who are depending on less frequent control and treatment intervals.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy